

How is IMI accelerating access to affordable innovative medicines

Lunch debate hosted by Françoise Grossetête MEP

Agenda 24.02.2016 • 12:30 – 14:30
Members' Salon
European Parliament
Brussels, Belgium
Registration

12:30 Introduction

Welcome address

Françoise Grossetête, Member of the European Parliament (MEP), EPP group, ENVI & D-RU Committees

Introduction to IMI

Pierre Meulien, Executive Director, Innovative Medicines Initiative (IMI)

13:00 The socio-economic impact of IMI's projects

Initial outcomes of the socio-economic impact report

Bengt Jönsson, Professor Emeritus, Department of Economics, Stockholm School of Economics

Perspective from the industry

Carlo Incerti, Head of Global Medical Affairs at Genzyme and member of the IMI Governing Board

The health technology assessment perspective

Pall Jonsson, Senior Scientific Adviser, Science Policy and Research Programme, National Institute for Health and Care Excellence (NICE)

Perspective from the European Commission

Andrzej Jan Rys, Director of Health systems, Medical Products and innovation, European Commission, DG Santé

Q&A

14:00 Concluding remarks

Pierre Meulien, IMI Executive Director

Networking